Patients treated for Merkel cell carcinoma (MCC) face a five-year recurrence rate of 40%—markedly higher than the recurrence rates for...

The immunotherapy medication pembrolizumab, approved for the treatment of stage III and IV melanoma, has been shown to reduce...